The Experts below are selected from a list of 28086 Experts worldwide ranked by ideXlab platform
Xingben Xiang - One of the best experts on this subject based on the ideXlab platform.
-
Improvement of the aroma of Lily rice wine by using aroma-producing yeast strain Wickerhamomyces anomalus HN006
AMB Express, 2019Co-Authors: Shoubao Yan, Chen Xiangsong, Xingben XiangAbstract:A fruity aroma-producing yeast strain was isolated with the aim of improving the aroma of fermented Lily rice wine, and identified as Wickerhamomyces anomalus HN006. In addition, the effects of adding solid residues of previous fermentation cycles, and of fungus α-amylase and W. anomalus HN006 supplementation on the biochemical parameters of Lily rice wine were evaluated. The optimum quality of the wine, in terms of ethanol and residual sugar content, acidity levels and aroma, was obtained with 5% (w/v) solid residue addition, and supplementation with 10 U/g fungal α-amylase and 2% (v/v) W. anomalus inoculum on the 4th day of fermentation. Volatile compound profiles, the total amount of amino acids and the sensory characteristics of the Lily rice wines produced by the two fermentation processes were also evaluated and compared. The Lily rice wine obtained from our optimized experimental technology produced higher amounts of some esters, free fatty acids, alcohols, aldehydes, ketones, alkenes, volatile phenol and thiazole, in addition to higher total amino acid content and sensory scores compared to the traditionally brewed wine. Our process resulted in an intensification and improvement of Lily rice wine aroma.
Shoubao Yan - One of the best experts on this subject based on the ideXlab platform.
-
Improvement of the aroma of Lily rice wine by using aroma-producing yeast strain Wickerhamomyces anomalus HN006
AMB Express, 2019Co-Authors: Shoubao Yan, Chen Xiangsong, Xingben XiangAbstract:A fruity aroma-producing yeast strain was isolated with the aim of improving the aroma of fermented Lily rice wine, and identified as Wickerhamomyces anomalus HN006. In addition, the effects of adding solid residues of previous fermentation cycles, and of fungus α-amylase and W. anomalus HN006 supplementation on the biochemical parameters of Lily rice wine were evaluated. The optimum quality of the wine, in terms of ethanol and residual sugar content, acidity levels and aroma, was obtained with 5% (w/v) solid residue addition, and supplementation with 10 U/g fungal α-amylase and 2% (v/v) W. anomalus inoculum on the 4th day of fermentation. Volatile compound profiles, the total amount of amino acids and the sensory characteristics of the Lily rice wines produced by the two fermentation processes were also evaluated and compared. The Lily rice wine obtained from our optimized experimental technology produced higher amounts of some esters, free fatty acids, alcohols, aldehydes, ketones, alkenes, volatile phenol and thiazole, in addition to higher total amino acid content and sensory scores compared to the traditionally brewed wine. Our process resulted in an intensification and improvement of Lily rice wine aroma.
Shi Jing-lue - One of the best experts on this subject based on the ideXlab platform.
-
Brewing Technology of Fermented Lily Wine
Food Science, 2009Co-Authors: Shi Jing-lueAbstract:Lily, which is rich in alkaloid and mineral substances, can be used for both food and drug. Using Lily and grape as the main raw materials, a fermented Lily wine with health functions was produced via wine yeast fermentation. The optimum technological parameters for the highest sensory score determined by orthogonal array design were as follows: fermenting at 23 ℃ for 9 days with a 20% addition of Lily juice, and then adding 40 mg/L chitosan for clarification. As a result, the produced Lily wine had high quality and clarity.
-
Study on the processing technology of Lily beer
China Brewing, 2008Co-Authors: Shi Jing-lueAbstract:Lily is a kind of nutrient food, as well as a kind of herb with good drug effect and health care function. Lily and malt being the primary raw material, a kind of nutritional Lily beer, with health care function, was developed by use of a small scale beer process in our college. The conditions for liquefaction and saccharification of Lily juice were discussed. The amount of Lily juice required is 4%, and the quality of the Lily beer will be better if the Lily juice is added at post-fermentation point.
-
Study on the rice wine with Lily
Jiangsu Condiment and Subsidiary Food, 2007Co-Authors: Shi Jing-lueAbstract:In order to meet consumers' need for health-care food,rice wine with Lily is developed.Lily and glutinous rice are mixed,saccharificated and fermented to produce health-care rice wine with Lily.Studies on Lily liquefaction and its adding manner are carried out to set the optimum conditions for Lily liquefaction as the followings:liquefaction temperature is 100℃,the adding amount of liquefied enzyme is 140 U/g of dry matter,liquefaction period is 25min and the optimal adding amount of liquefied Lily is about 10%.
Johanna E. Stenberg - One of the best experts on this subject based on the ideXlab platform.
-
Herbivory limits the yellow water Lily in an overgrown lake and in flowing water
Hydrobiologia, 2012Co-Authors: Johan A. Stenberg, Johanna E. StenbergAbstract:Aquatic macrophytes with floating leaves are often key ecological species that affect entire aquatic ecosystems. Here we describe an investigation of the importance of insect herbivory for population growth and leaf senescence in the yellow water Lily ( Nuphar lutea ). In order to gain a general picture of the importance of herbivory under different conditions, we experimentally manipulated herbivory in a large Lily population in natural still water and observed the natural development of 32 smaller populations in flowing water. Herbivory drastically increased leaf senescence, reducing leaf density. In the still water, over one summer, leaf density increased by a factor of 1.23 in the presence of water Lily leaf beetles and 1.61 when herbivory was eliminated. In flowing water, population growth was restricted mainly by leaf crowdedness, which limited large dense populations. Herbivory by water Lily leaf beetles also had a limiting effect on yellow water Lily, again mainly in large dense populations. Small populations supported a lower density of beetles. Previous studies have not addressed population-level responses of vascular plants with floating leaves. Our results suggest that herbivory can result in greater light penetration into the water and reduce “enemy-free space” for aquatic species that find such space in water Lily stands. We suggest that the water Lily leaf beetle should be considered an “ecological engineer.”
Alan W Friedman - One of the best experts on this subject based on the ideXlab platform.
-
thu0174 characterization of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators
Annals of the Rheumatic Diseases, 2019Co-Authors: Stephen Hall, Paul Emery, Tsutomu Takeuchi, Glen Thomson, Bernard Combe, Andrea Everding, K Pavelka, Y Song, Tim Shaw, Alan W FriedmanAbstract:Background Across all phase 3 studies, treatment with upadacitinib (UPA), a JAK1-selective inhibitor, was associated with significantly higher remission (REM) rates, compared to placebo (PBO) or active comparators, in RA patients (pts) who were methotrexate (MTX)-naive, had inadequate response to conventional synthetic (csDMARD-IR) or had inadequate response or intolerance to biologic DMARDs (bDMARD-IR) Objectives REM definitions are based on composite scores of various individual assessments of disease activity. To determine the response to UPA on REM and component assessments, we assessed the proportions of pts achieving REM using multiple REM definitions, and the improvement in their respective individual components, compared to PBO or active comparators, in 3 different RA pt populations spanning a range of RA pt populations. Methods Three phase 3 studies included pts who were MTX naive (SELECT EARLY, n=945), MTX-IR (SELECT COMPARE, n=1629) and bDMARD-IR (SELECT BEYOND, n=498). The proportion of pts achieving REM at Week (Wk) 12 by 4 definitions (DAS28-CRP Results Pt demographics and disease characteristics have been previously reported. 1-3 At 12 wks, in EARLY and COMPARE, a significantly greater proportion of pts receiving UPA 15 mg or 30 mg QD achieved REM by all 4 definitions vs MTX, PBO or ADA (Table). In BEYOND, (a refractory population many of whom had inadequate response to multiple bDMARDs), a significantly greater proportion of pts receiving UPA 30mg achieved all REM definitions vs PBO within the first 12 wks, with significantly greater proportions on UPA 15mg achieving DAS28-CRP 1 Compared to respective control groups, pts receiving UPA 15 or 30 mg QD had significantly greater improvements in each REM disease component (except for PhGA vs ADA in COMPARE). Significantly more pts receiving UPA also achieved the required cutoffs on the individual components of Boolean REM compared to respective controls. Conclusion Significantly greater proportions of pts receiving UPA 15 or 30mg achieved REM by multiple definitions at 12 wks compared to PBO, MTX or ADA. All disease activity components of each REM definition were significantly improved in pts receiving UPA compared to MTX or PBO, and all Boolean components were significantly improved in pts receiving UPA 15mg compared to ADA. References [1] Genovese, et al. 2018;Lancet.18;31116-4. [2] van Vollenhoven R, et al. Arthritis Rheumatol. 2018;70 (supp10). [3] Fleischmann, et al. Arthritis Rheumatol. 2018;70 (supp10). Acknowledgement AbbVie, Inc was the study sponsor, contributed to study design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version. Medical writing support was provided by Naina Barretto, PhD, of AbbVie, Inc. Disclosure of Interests Stephen Hall Grant/research support from: AbbVie Inc, BMS, Lilly, Janssen, Pfizer, UCB, and Novartis, Consultant for: AbbVie Inc, BMS, Lilly, Janssen, Pfizer, UCB, and Novartis, Tsutomu Takeuchi Grant/research support from: Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Eisai Co., Ltd., AYUMI Pharmaceutical Corporation, Nipponkayaku Co. Ltd., Novartis Pharma K.K., Grant/research support from: AbbVie, Asahi Kasei, Astellas, AstraZeneca, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer Japan Inc, Taiho, Taisho Toyama, Takeda, Teijin, Grant/research support from: Astellas Pharma Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Taisho Toyama Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., Celltrion Inc., Nipponkayaku Co. Ltd., and UCB Japan, Consultant for: Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Abbivie GK, Nipponkayaku Co.Ltd, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., GlaxoSmithKline K.K., UCB Japan Co. Ltd., Consultant for: AbbVie, Asahi Kasei, Astellas, AstraZeneca, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer Japan Inc, Taiho, Taisho Toyama, Takeda, Teijin, Consultant for: Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Asahi Kasei Medical K.K., AbbVie GK, Daiichi Sankyo Co., Ltd., Bristol Myers Squibb, and Nipponkayaku Co. Ltd., Speakers bureau: Astellas Pharma Inc., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Taisho Toyama Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., Celltrion Inc., Nipponkayaku Co. Ltd., and UCB Japan, Speakers bureau: AbbVie, Asahi Kasei, Astellas, AstraZeneca, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer Japan Inc, Taiho, Taisho Toyama, Takeda, Teijin, Speakers bureau: AbbVie GK., Bristol–Myers K.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Astellas Pharma Inc, Diaichi Sankyo Co. Ltd., Eisai Co. Ltd., Sanofi K.K., Teijin Pharma Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K., Glen Thomson Grant/research support from: AbbVie, Consultant for: Amgen, Paul Emery Grant/research support from: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche, Consultant for: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Gilead,Samsung, Sandoz and Lilly, Bernard Combe Consultant for: Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche-Chugai, Sanofi, UCB, Andrea Everding: None declared, Karel Pavelka: None declared, Yanna Song Shareholder of: AbbVie, Employee of: AbbVie, Tim Shaw Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, Alan Friedman Shareholder of: AbbVie, Employee of: AbbVie, In-Ho Song Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, Eduardo Mysler Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Janssen, Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lily, Janssen, Medimmune, Pfizer Inc, and Roche, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lily, Janssen, Medimmune, Pfizer Inc, and Roche, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Janssen, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lily, Janssen, Medimmune, Pfizer Inc, and Roche